Disclaimer: This article is provided for educational and research purposes only. The compounds discussed are investigational and are not presented as medicines, treatments, or recommendations for human use.
Introduction
Selective Androgen Receptor Modulators — better known as SARMs — have become one of the most prominent classes of investigational compounds in modern physique, performance and androgen research.
Much of that interest comes from a relatively simple scientific idea: could researchers stimulate useful androgen-receptor activity in tissues such as muscle and bone while producing a more selective overall response than traditional androgenic compounds?
That possibility has driven pharmaceutical research into SARMs for conditions involving muscle wasting, loss of lean tissue, physical frailty and bone health. At the same time, research demonstrating measurable changes in areas such as lean body mass and body composition has helped make SARMs particularly prominent within strength, physique and performance-related research.
However, the science is considerably more complicated than many commercial descriptions suggest.
Different SARMs have different chemical structures, receptor characteristics, pharmacokinetics and research histories. Some compounds commonly grouped alongside SARMs — including MK-677 and Cardarine — are not actually selective androgen receptor modulators at all.
This guide examines what SARMs are, how they work, why they have attracted so much interest, what research actually says about their effects, the major compounds within the category, and why identity, purity and independent testing matter when evaluating research compounds.
What Are SARMs?
SARMs stands for Selective Androgen Receptor Modulators.
The androgen receptor is a cellular receptor involved in many of the biological effects associated with androgens such as testosterone.
Traditional androgenic compounds can activate androgen receptors throughout numerous tissues. The scientific objective behind SARMs was to investigate whether molecules could be developed that produced a more selective pattern of androgen-receptor activity.
Researchers were particularly interested in whether this might retain useful anabolic activity in tissues such as skeletal muscle and bone while reducing some of the unwanted effects associated with less selective androgen therapies.
This concept led to the development of numerous experimental compounds with different structures and pharmacological characteristics.
That potential selectivity is one of the principal reasons SARMs became so scientifically and commercially interesting.
Rather than simply reproducing testosterone pharmacology, researchers were attempting to create compounds capable of influencing androgen-receptor signalling in a more targeted way.
Some SARMs have subsequently demonstrated measurable effects on lean body mass and other body-composition markers during clinical research.
However, the extent to which tissue selectivity observed experimentally translates into meaningful advantages in humans remains an important scientific question.
SARMs should therefore be viewed as an active area of pharmaceutical and performance-related research rather than a uniform group of compounds with identical effects.
How Do SARMs Work?
SARMs interact with the androgen receptor, a type of nuclear receptor located within cells.
When an appropriate molecule binds to that receptor, it can influence gene transcription and downstream biological processes.
Androgen-receptor signalling has important roles in tissues including:
skeletal muscle
bone
reproductive tissues
the central nervous system
other androgen-responsive tissues
The attraction of selective androgen receptor modulation is that different molecules may produce different patterns of receptor activation depending on factors including:
molecular structure
receptor-binding characteristics
tissue distribution
metabolism
receptor conformation
recruitment of transcriptional co-regulators
This is important when discussing potential results.
Two compounds labelled as SARMs should not automatically be expected to behave identically.
A compound’s influence on lean tissue, endocrine markers or other biological outcomes depends upon its individual pharmacology rather than simply the fact that it belongs to the broader SARM category.
One of the major objectives of ongoing research is therefore determining whether selective androgen-receptor activation can produce useful effects in muscle and bone while achieving a more favourable overall profile than conventional androgen therapies.
Why Were SARMs Developed?
Much of the pharmaceutical interest in SARMs originated from the limitations associated with conventional androgen therapy.
Researchers have investigated selective androgen receptor modulation in areas including:
sarcopenia
age-related loss of muscle mass
cachexia and disease-associated muscle wasting
physical frailty
osteoporosis and bone health
recovery of lean tissue following serious illness
conditions involving impaired physical function
These applications explain why muscle mass, lean tissue and physical performance frequently appear within SARM research.
The theoretical goal was highly attractive: retain useful anabolic activity where required while reducing activity in tissues where androgenic effects may be less desirable.
Clinical results have provided some evidence supporting parts of that concept.
Several investigational SARMs have produced measurable increases in lean body mass.
That finding has understandably contributed to their wider popularity within performance and physique-related research.
However, increases in lean body mass have not always translated into similarly consistent improvements in outcomes such as strength, mobility or functional performance.
This distinction is important.
It is reasonable to say that SARMs have demonstrated interesting body-composition effects in research.
It is not accurate to assume that every compound therefore produces predictable improvements in athletic performance.
Why Have SARMs Become So Popular in Performance and Physique Research?
The commercial interest surrounding SARMs is closely connected to the areas researchers originally sought to influence.
Muscle tissue, body composition, bone health and androgen signalling are naturally highly relevant subjects within strength and physique science.
When clinical trials began reporting measurable changes in lean body mass for some selective androgen receptor modulators, interest expanded well beyond traditional pharmaceutical research.
SARMs consequently became associated with questions surrounding:
lean tissue
muscle preservation
body composition
strength research
recovery
androgen-receptor signalling
performance physiology
This helps explain why compounds such as Ostarine, LGD-4033 and RAD-140 receive considerably more attention than many other investigational molecules.
There is a clear intersection between their scientific mechanisms and areas of strong interest within sports science.
However, commercial popularity and scientific certainty are two different things.
Some SARMs have considerably stronger human evidence than others, while certain compounds remain supported primarily by preclinical research.
Understanding those differences is essential when comparing individual SARMs.
The Main SARMs Explained
Numerous experimental selective androgen receptor modulators have been developed.
Among the compounds most commonly encountered in contemporary research are:
RAD-140
Ostarine / MK-2866
LGD-4033
YK-11
Each has its own research history, and their respective evidence bases should not be treated as interchangeable.
RAD-140 — Testolone
RAD-140, commonly known as Testolone, is a non-steroidal selective androgen receptor modulator originally developed as an investigational compound.
It has attracted considerable interest because of its interaction with androgen receptors and the tissue-selective characteristics observed during experimental research.
RAD-140 has subsequently become one of the most recognisable SARMs within strength and physique-related research.
Its appeal is understandable from a mechanistic perspective.
Androgen-receptor signalling plays an important role in skeletal muscle biology, while RAD-140 was specifically developed as a selective androgen-receptor-active compound.
However, the available evidence must still be interpreted according to the type of research performed.
A significant proportion of the data surrounding RAD-140 comes from preclinical investigation rather than the extensive human clinical programmes available for some other investigational compounds.
Unlike testosterone and traditional steroidal androgens, RAD-140 possesses a non-steroidal chemical structure.
That distinction reflects the wider objective behind SARM development: investigating whether androgen-receptor signalling could be influenced without recreating the complete pharmacological behaviour of conventional steroidal androgens.
For a deeper look at the available evidence, see our RAD-140 research article examining the compound from a scientific and research-focused perspective.
Ostarine — MK-2866 / Enobosarm
Ostarine, also known as MK-2866 or Enobosarm, is one of the most extensively researched selective androgen receptor modulators.
This makes Ostarine particularly important when examining claims surrounding SARMs because it has undergone considerably more human clinical investigation than many compounds within the category.
Clinical research has investigated Ostarine in populations affected by reductions in lean tissue and physical function.
Studies have reported measurable changes in lean body mass, helping establish much of the wider interest surrounding selective androgen receptor modulation and body composition.
That research history has also contributed to Ostarine becoming one of the most widely recognised SARMs within physique and performance-related discussions.
However, increases in lean mass should not automatically be interpreted as evidence of proportionate improvements in strength or athletic performance.
The significance of any result depends on the population, trial design, duration and measured endpoint.
Ostarine remains an investigational compound rather than an approved general treatment.
For a closer look at the published evidence and research context, see our Ostarine research article covering MK-2866 / Enobosarm in greater detail.
LGD-4033 — Ligandrol
LGD-4033, commonly known as Ligandrol, is another non-steroidal selective androgen receptor modulator that has undergone human clinical investigation.
Research has examined its pharmacokinetics, androgen-receptor activity and influence on measures including lean body mass.
Those findings have made LGD-4033 particularly relevant within discussions surrounding body composition and muscle-related research.
The interest is again closely connected to the original SARM concept: producing useful anabolic signalling while achieving a different pattern of activity from conventional androgenic compounds.
Importantly, research has also demonstrated that the word selective should not be interpreted as meaning biologically isolated.
Changes in endocrine and metabolic markers have been observed during clinical investigation.
This reinforces why LGD-4033 should be viewed as a pharmacologically active investigational compound rather than as a conventional nutritional supplement.
For a closer comparison of LGD-4033 and Ostarine within muscle-retention research, see our LGD-4033 research comparison examining how the two compounds differ.
YK-11
YK-11 is frequently marketed and discussed alongside SARMs, although its pharmacology differs somewhat from better-characterised compounds such as Ostarine, LGD-4033 and RAD-140.
It has demonstrated androgen-receptor activity in laboratory research and has attracted interest because of experimental findings associated with pathways involved in myogenic differentiation.
This has contributed to substantial commercial interest in YK-11 within muscle and physique-related research.
However, there is an important limitation.
The amount of published human research available for YK-11 is substantially smaller than for compounds such as Enobosarm.
Claims surrounding YK-11 therefore need to distinguish carefully between:
laboratory evidence
mechanistic hypotheses
animal or preclinical evidence
demonstrated human outcomes
A mechanism that appears interesting in laboratory research does not automatically establish a particular result in humans.
For a closer look at its distinctive mechanism and the limits of the current evidence, see our YK-11 research article examining androgen-receptor and myostatin-related signalling in greater detail.
Are MK-677 and Cardarine SARMs?
Technically, no.
This is one of the most common sources of confusion surrounding research compounds.
MK-677 and Cardarine frequently appear alongside SARMs because they are discussed within similar physique and performance-research contexts.
However, neither compound selectively modulates the androgen receptor.
Their mechanisms are fundamentally different.
MK-677 / Ibutamoren
MK-677, also known as Ibutamoren, is a ghrelin-receptor agonist and growth-hormone secretagogue.
Research has investigated its effects on growth hormone, IGF-1, body composition and other physiological outcomes.
That research explains why MK-677 is frequently discussed alongside SARMs despite belonging to a completely different pharmacological class.
Its commercial association with SARMs is therefore based more on overlapping areas of research interest than on mechanism.
For a deeper look at the evidence behind Ibutamoren, see our MK-677 research article covering its mechanism, published findings and current research context.
Cardarine / GW501516
Cardarine, also known as GW501516, is a PPAR-delta agonist rather than a selective androgen receptor modulator.
Research involving PPAR-delta has generated interest in areas associated with metabolism and endurance physiology.
Again, this explains why Cardarine is frequently grouped commercially alongside SARMs even though the underlying mechanism is entirely different.
For a deeper look at GW-501516 and its role in metabolic and mitochondrial signalling, see our Cardarine research article exploring the compound’s scientific context in greater detail.
Grouping compounds together commercially does not make them members of the same pharmacological class.
Accurate classification matters when interpreting research and comparing potential effects.
What Does SARM Research Actually Show?
This is arguably the most important question surrounding the entire category.
One reason SARMs have maintained such strong scientific and commercial interest is that some investigational compounds have produced measurable biological effects in human studies.
Among the most notable findings are changes in lean body mass.
That is clearly relevant to research surrounding:
muscle preservation
body composition
age-related muscle loss
recovery from disease-associated wasting
physical performance
However, the interpretation needs to remain precise.
An increase in lean body mass does not automatically demonstrate an improvement in strength, athletic performance or physical function.
Clinical trials have produced mixed results when researchers have examined these broader outcomes.
Some compounds have demonstrated promising changes in body composition while improvements in strength, mobility or functional measures have been less consistent.
This helps explain both sides of the SARMs story.
There is enough research demonstrating genuine biological activity to explain why the category attracts considerable attention.
At the same time, the evidence does not justify treating all SARMs as proven performance-enhancing compounds with predictable results.
Research should always be interpreted according to what was actually measured.
Are SARMs More Selective Than Testosterone?
The aim behind SARM development was to produce a more selective pattern of androgen-receptor activity than traditional androgenic compounds.
In preclinical models, tissue selectivity has been demonstrated for various experimental SARMs.
The more difficult question is how meaningful that selectivity ultimately becomes in humans.
A compound can be more selective without being completely tissue-specific.
Androgen-receptor activity can still influence multiple biological systems.
This is why researchers examine not only potential effects on muscle and bone but also:
endocrine markers
lipids
liver-related markers
cardiovascular parameters
other systemic effects
Selectivity should therefore be viewed as a relative pharmacological characteristic, not as a guarantee that activity is confined only to skeletal muscle.
Are SARMs Steroids?
SARMs and anabolic-androgenic steroids both interact with androgen signalling, but they are not synonymous.
Many of the best-known SARMs — including Ostarine, LGD-4033 and RAD-140 — are non-steroidal molecules.
Anabolic steroids are generally based upon the steroidal structure of testosterone or related hormones.
The compounds can therefore differ considerably in:
molecular structure
metabolism
receptor interactions
tissue distribution
pharmacokinetics
downstream biological effects
The original development of non-steroidal SARMs was partly motivated by the possibility of producing androgen-receptor activity with a different pharmacological profile from conventional steroid hormones.
This distinction is central to understanding why SARMs generated so much pharmaceutical interest in the first place.
Does “Selective” Mean Side-Effect Free?
No.
The word selective is sometimes misunderstood.
It refers to the objective of achieving differing patterns of activity across tissues.
It does not mean that a compound acts exclusively on skeletal muscle.
It also does not mean that a compound is free from adverse biological effects.
Clinical research and published case reports have identified potential effects involving markers associated with:
liver function
endocrine function
lipid metabolism
cardiovascular health
Long-term safety remains insufficiently characterised for many compounds within the SARM category.
This matters particularly when interpreting commercial claims.
A product can be interesting from a muscle or body-composition research perspective while still having important unanswered questions surrounding other physiological systems.
Scientific discussion needs to reflect both sides of that equation.
SARMs and Competitive Sport
Athletes subject to anti-doping rules should understand that selective androgen receptor modulators are prohibited.
The World Anti-Doping Agency (WADA) includes SARMs within the category of other anabolic agents.
They are prohibited at all times, including both in competition and out of competition.
Compounds associated with the prohibited class include:
Ostarine / Enobosarm
LGD-4033 / Ligandrol
RAD-140
Andarine
S-23
Other compounds commonly sold alongside SARMs may fall within separate prohibited categories.
Competitive athletes should therefore refer directly to the current WADA Prohibited List and their governing body’s rules.
Why Research-Compound Purity Matters
The growing commercial interest surrounding SARMs has also created an important quality-control issue.
A label stating that a product contains a particular compound does not itself prove that the material inside actually contains the stated substance at the stated purity or concentration.
Published investigations of products sold within the research-compound market have identified examples involving:
incorrect active ingredients
quantities differing from label claims
undeclared substances
mixtures of multiple compounds
products containing none of the stated active ingredient
For researchers, this presents a fundamental problem.
If the material under investigation cannot be confidently identified, observations obtained from that material cannot reliably be attributed to the intended compound.
Purity is therefore not merely a marketing point. It is fundamental to meaningful research.
You can read more about our approach to independent testing and quality verification on our dedicated Testing & Quality page.
What Should a Research Compound Certificate of Analysis Show?
A meaningful Certificate of Analysis — or CoA — should provide considerably more information than a simple statement that a sample has passed a test.
Depending upon the analytical method and material being examined, useful documentation may include:
product or sample identification
batch or lot reference
analytical method
testing date
measured purity or assay result
laboratory identification
chromatographic or analytical information where relevant
Techniques such as HPLC — High-Performance Liquid Chromatography — are commonly used when assessing chemical purity.
Other analytical techniques may be required to establish identity or examine different characteristics of a compound.
The most important principle is traceability.
A research product should be capable of being connected to meaningful analytical evidence rather than relying solely upon a manufacturer’s marketing claim.
Research Compound Testing at Affordable Nutrition UK
At Affordable Nutrition UK, product identity, analytical quality and transparency form an important part of our approach to research compounds.
Where applicable, products are supported by independent analytical testing and Certificates of Analysis, allowing researchers to examine relevant purity information rather than relying solely upon stated specifications.
Our approach places particular emphasis on:
independent testing
purity verification
Certificates of Analysis
batch information
manufacturing standards
product traceability
This becomes increasingly important with research compounds because two apparently identical products from different suppliers may not necessarily contain materials of equivalent quality or purity.
Visitors can learn more through our dedicated Testing & Quality section.
Why SARMs Should Not Be Treated as One Compound
One of the biggest mistakes in discussions surrounding SARMs is treating the term as though it describes one substance.
It does not.
“SARM” describes a pharmacological class.
RAD-140 is not Ostarine.
Ostarine is not LGD-4033.
LGD-4033 is not YK-11.
Each compound has its own:
molecular structure
receptor characteristics
pharmacokinetics
experimental history
evidence base
limitations
Their relative commercial popularity also should not be confused with the strength of their respective evidence bases.
Some SARMs have undergone human clinical trials.
Others remain supported predominantly by laboratory or animal research.
The sensible approach is therefore to assess each compound according to its own published evidence rather than transferring claims from one SARM to another.
SARMs vs SERMs: What Is the Difference?
SARMs and SERMs are sometimes confused because their names appear similar.
They are completely different classes of compound.
SARM means:
Selective Androgen Receptor Modulator
whereas:
SERM means:
Selective Oestrogen Receptor Modulator
SERMs interact primarily with oestrogen receptors rather than androgen receptors.
Examples of compounds associated with selective oestrogen-receptor modulation include:
Clomiphene
Enclomiphene
Enclomiphene has attracted significant research interest in areas involving reproductive endocrinology and testosterone regulation, but its mechanism is fundamentally different from SARMs.
For a more detailed look at how this SERM works and the evidence behind its effects on testosterone regulation, see our Enclomiphene research guide.
Choosing Reliable Scientific Information About SARMs
The popularity of SARMs means there is now an enormous amount of information available online.
Unfortunately, the quality of that information varies considerably.
When researching an individual compound, greater weight should generally be given to:
Peer-reviewed research
Clinical trials and peer-reviewed scientific papers provide considerably stronger evidence than anecdotal claims.
Primary studies
Whenever possible, examine the original research rather than relying entirely on somebody else’s interpretation.
Compound-specific evidence
Do not assume research involving one SARM automatically applies to another.
Human versus preclinical research
Results obtained from cultured cells or animal models can provide valuable mechanistic information but cannot automatically be extrapolated into human outcomes.
Measured outcomes
Look carefully at what researchers actually measured.
For example:
increased lean body mass
does not automatically mean:
increased strength
and neither automatically demonstrates:
improved athletic performance.
Research quality
Study population, duration, control groups, sample size and research design all influence how strongly a result can be interpreted.
This distinction is particularly important in a commercially popular category where claims can sometimes move considerably faster than the underlying science.
Affordable Nutrition UK SARMs Research Range
Affordable Nutrition UK provides a range of research compounds alongside educational material designed to make individual compounds easier to investigate and compare.
Our SARMs research range includes compounds such as:
RAD-140 / Testolone
A non-steroidal selective androgen receptor modulator with a substantial preclinical research history and significant interest within androgen and muscle-related research.
Ostarine / MK-2866 / Enobosarm
One of the most extensively clinically investigated selective androgen receptor modulators, including research involving lean body mass and physical function.
LGD-4033 / Ligandrol
A selective androgen receptor modulator that has undergone human pharmacokinetic and body-composition research.
YK-11
An androgen-receptor-active experimental compound commonly discussed alongside more extensively characterised SARMs.
You can explore the complete range through our dedicated SARMs category.
Frequently Asked Questions About SARMs
What does SARM stand for?
SARM stands for Selective Androgen Receptor Modulator. The term describes compounds developed to interact selectively with androgen receptors and potentially produce differing patterns of activity across tissues.
Why are SARMs associated with muscle and body-composition research?
Androgen-receptor signalling plays an important role in skeletal muscle biology, and several investigational SARMs have been studied for conditions involving loss of lean tissue. Some clinical trials have reported increases in lean body mass, which has contributed considerably to wider interest in the category.
Have SARMs been shown to increase lean body mass?
Certain SARMs have produced measurable increases in lean body mass during human clinical research. However, results vary between compounds and an increase in lean mass should not automatically be interpreted as proof of improved strength or athletic performance.
Are all SARMs the same?
No. SARMs are a class of compounds rather than one substance. RAD-140, Ostarine and LGD-4033 have different molecular structures, pharmacological characteristics and research histories.
Is MK-677 a SARM?
No. MK-677, or Ibutamoren, is a ghrelin-receptor agonist and growth-hormone secretagogue. It is frequently grouped commercially with SARMs because of overlapping research interests but has a completely different mechanism.
Is Cardarine a SARM?
No. Cardarine, or GW501516, is a PPAR-delta agonist rather than a selective androgen receptor modulator.
Is Ostarine a SARM?
Yes. Ostarine — also known as MK-2866 or Enobosarm — is a selective androgen receptor modulator and is one of the more extensively researched compounds within the category.
Is RAD-140 a SARM?
Yes. RAD-140, commonly known as Testolone, is an experimental non-steroidal selective androgen receptor modulator.
Is LGD-4033 a SARM?
Yes. LGD-4033, or Ligandrol, is a selective androgen receptor modulator that has undergone human research.
Are SARMs steroids?
Most commonly discussed SARMs such as Ostarine, RAD-140 and LGD-4033 are non-steroidal molecules, although both SARMs and anabolic steroids influence androgen-receptor signalling.
Are SARMs prohibited in competitive sport?
Yes. SARMs are included on the World Anti-Doping Agency Prohibited List and are prohibited at all times for athletes governed by WADA rules.
Are SARMs approved medicines?
SARMs remain investigational compounds rather than generally approved medicines. Research into potential clinical applications continues.
Why is independent testing important for research compounds?
Independent testing can provide evidence regarding the identity and purity of the material being examined. Without reliable analytical verification, experimental findings may be compromised by incorrectly labelled or contaminated material.
The Future of SARM Research
More than two decades after selective androgen receptor modulators became a major area of pharmaceutical research, their scientific story remains unfinished.
The original concept remains attractive:
develop compounds capable of producing useful androgen-receptor activity — particularly in tissues such as muscle and bone — while achieving greater selectivity than traditional androgen therapies.
Researchers have demonstrated that some SARMs can influence lean body mass, body composition and other biological outcomes.
Those findings explain much of the continuing interest surrounding the category.
What has proved considerably more difficult is demonstrating consistent improvements in clinically meaningful physical performance while simultaneously establishing a sufficiently well-characterised long-term safety profile.
That tension is what makes the SARM category scientifically interesting.
They are neither inactive compounds nor simple nutritional supplements.
They are pharmacologically active investigational molecules whose effects can vary considerably according to structure, dose, research model and individual compound.
Continued pharmaceutical research will determine whether certain SARMs eventually find specialised clinical applications.
Until then, understanding the differences between compounds — and separating measured research findings from commercial extrapolation — remains essential.
Important Information
This article is provided for scientific and educational purposes. Research compounds discussed on Affordable Nutrition UK are not presented as medicines or treatments for medical conditions. Competitive athletes should consult the current World Anti-Doping Agency Prohibited List and the rules of their relevant governing body.
Scientific References
Bond P, Smit DL, Verdegaal T, de Ronde W. Selective androgen receptor modulators: a critical appraisal. Frontiers in Endocrinology, 2025.
Pena Dias J, Dobs AS. Will Selective Androgen Receptor Modulators Ever Reach the Clinic? Journal of Clinical Endocrinology & Metabolism, 2026.
Solomon ZJ et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews, 2019.
Vasireddi N et al. Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review. American Journal of Sports Medicine.
Harris DR et al. Selective Androgen Receptor Modulators: A Review of Their Therapeutic Promise and Concerns of Misuse. Current Sports Medicine Reports, 2026.
World Anti-Doping Agency. 2026 World Anti-Doping Code — Prohibited List.
U.S. Anti-Doping Agency. Selective Androgen Receptor Modulators (SARMs): What Athletes Need to Know.